Placeholder

Cefoxitin Sodium

  • # LGM Pharma is a Cefoxitin Sodium CAS# 33564-30-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Cefoxitin Sodium
  • CAS #: 33564-30-6
  • Mode of Action:

    The bactericidal action of cefoxitin results from inhibition of cell wall synthesis.

  • Pharmacodynamics:

    Cefoxitin is a cephamycin antibiotic often grouped with the second-generation cephalosporins. It is active against a broad range of gram-negative bacteria including anaerobes. The methoxy group in the 7a position provides cefoxitin with a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases, of gram-negative bacteria.

  • Metabolism:

    Minimal (approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period).

  • Toxicity:

    The acute intravenous LD50 in the adult female mouse and rabbit was about 8.0 g/kg and greater than 1.0 g/kg, respectively. The acute intraperitoneal LD50 in the adult rat was greater than 10.0 g/kg.

  • ATC: J01DC01
  • PubChem: 441199
  • DrugBank: DB01331
  • Formula: C16-H16-N3-Na-O7-S2 C16-H16-N3-O7-S2.Na C16-H17-N3-O7-S2.Na
  • Molecular Mass: 449.4384
  • Synonyms: 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, sodium salt, (6R-cis)-, Betacef, Cefoxil, Cefoxitin, Cefoxitin and dextrose in duplex container, Cefoxitin sodium, Cefoxitin sodium salt, Cefoxotin sodium, Cenomycin, EINECS 251-574-6, L 620388, Mefoxin, Mefoxin in dextrose 5% in plastic container, Mefoxin in plastic container, Mefoxin in sodium chloride 0.9% in plastic container, Mefoxitin, Merxin, MK 206, Monosodium cefoxitin, Sodium (6R,7S)-3-(hydroxymethyl)-7-methoxy-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate carbamate (ester), UNII-Q68050H03T
  • SMILES: CO[C@@]1([C@@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)[O-])NC(=O)Cc3cccs3.[Na+]
  • AHFS Code: 08:12.07.12
  • InChl: 1S/C16H17N3O7S2.Na/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19;/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22);/q;+1/p-1/t14-,16+;/m1./s1
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service